HOAP-Bleo as salvage therapy for diffuse aggressive non-Hodgkin's lymphoma

1988 ◽  
Vol 22 (2) ◽  
Author(s):  
R. Liang ◽  
D. Todd ◽  
T.K. Chan
Keyword(s):  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals ESHAP as Salvage Therapy for Refractory Non-Hodgkin's Lymphoma: Taiwan Experience

1999 ◽  
Vol 29 (1) ◽  
pp. 33-37 ◽  
Author(s):  
W.-S. Wang ◽  
T.-J. Chiou ◽  
J.-H. Liu ◽  
F. S. Fan ◽  
C.-C. Yen ◽  
...  
Keyword(s):  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma.

1994 ◽  
Vol 12 (4) ◽  
pp. 788-792 ◽  
Author(s):  
M Hoffman ◽  
M S Tallman ◽  
D Hakimian ◽  
D Janson ◽  
D Hogan ◽  
...  
Keyword(s):  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Response Rate ◽  
Complete Response ◽  
Hodgkin's Lymphoma ◽  
Chemotherapy Drugs ◽  
Non Hodgkin’S Lymphoma ◽  
Major Toxicity ◽  
Non Hodgkin's Lymphoma ◽  
Pretreated Patients

PURPOSE To determine the response rate to 2-chlorodeoxyadenosine (2-CdA; cladribine) in patients with advanced indolent non-Hodgkin's lymphoma (NHL) who fail to respond to or progress after a response to standard chemotherapy drugs. PATIENTS AND METHODS Twenty-one patients were treated with at least one cycle of 2-CdA 0.1 mg/kg/d by continuous infusion for 5 or 7 days. RESULTS The overall response rate (complete response [CR] and partial response [PR]) was nine of 21 patients (43%; 95% confidence interval, 22% to 64%). Unmaintained durable responses (longest follow-up, 29+ months) have been observed. The treatment was well tolerated by all patients. The major toxicity was related to myelosuppression (predominantly neutropenia) and immunosuppression with infection. CONCLUSION The purine analog 2-CdA is an active salvage therapy in pretreated patients with indolent NHL, and deserves further assessment in untreated patients and in combination with other chemotherapy agents.

Response to Re-Treatment with Rituximab Plus Salvage-Chemotherapy in Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 4720-4720 ◽  
Author(s):  
Andrea Borgerding ◽  
Justin Hasenkamp ◽  
Bjoern Chapuy ◽  
Lorenz Truemper ◽  
Gerald Wulf ◽  
...  
Keyword(s):  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Progressive Disease ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Salvage Chemotherapy ◽  
Hodgkin's Lymphoma ◽  
Autologous Graft ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Abstract The efficacy of re-therapy with rituximab immuno-chemotherapy was analysed in 20 consecutive patients with relapsed or progressive aggressive Non Hodgkin’s lymphoma after initial treatment with rituximab plus chemotherapy. Ten patients had a diffuse large B-cell lymphoma, seven had a mantle cell lymphoma and three a grade III follicular lymphoma. At primary diagnosis, the IPI was high-intermediate or high in 75% of the patients and the median age was 55 years (range 36–72 years). The overall response rate of primary immuno-chemotherapy was 75% (15/20 patients) with a complete remission in 8/20 patients (40%). After relapse, 53 % of these patients (8/15) responded again to immunochemotherapy: two patients had a second complete and six a second partial remission. None of the five patients with primary progressive disease responded to a conventional immuno-chemo salvage therapy. After re-therapy with rituximab plus salvage chemotherapy, ten patients received at least one cycle of high dose chemotherapy followed by SCT. One patient did receive HD-chemotherapy and an autologous graft solely, two patients did receive HD-radio-immunotherapy followed by an autologous graft and seven patients finally received HDT and an allogeneic transplant. Allogeneic SCT resulted in a CR in 6 out of 7 patients. One of these ten patients relapsed after HDT consolidation. Six out of ten patients without HDT consolidation after immuno-chemotherapy progressed after secondary treatment, 4 patients are alive without progression (SD, PR) but follow up is short (7, 10, 13 and 16 months). Conclusion: A substantial proportion (53%) of patients with relapse after rituximab immuno-chemotherapy did response to rituximab containing salvage therapy. Patients with progressive disease under immuno-chemotherapy did not respond to such salvage therapy. Without additional consolidation by HDT the risk of progression after successful salvage with rituximab and salvage-chemotherapy is high.

Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin

1992 ◽  
Vol 30 (3) ◽  
pp. 243-244 ◽  
Author(s):  
Nissim Haim ◽  
Edward Rosenblatt ◽  
Mira Wollner ◽  
Menachem Ben-Shahar ◽  
Ron Epelbaum ◽  
...  
Keyword(s):  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma

2007 ◽  
Vol 48 (6) ◽  
pp. 1092-1101 ◽  
Author(s):  
Tadeusz Robak ◽  
Ewa Lech-Maranda ◽  
Agnieszka Janus ◽  
Jerzy Blonski ◽  
Agnieszka Wierzbowska ◽  
...  
Keyword(s):  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

scholarly journals Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma

Cancer ◽  
1989 ◽  
Vol 64 (7) ◽  
pp. 1388-1392 ◽  
Author(s):  
Anthony D. Ho ◽  
Fransisco Del Valle ◽  
Heide Rückle ◽  
Jürgen Schwammborn ◽  
Günter Schlimok ◽  
...  
Keyword(s):  
Salvage Therapy ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
High Dose ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
High Dose Cytarabine
Sign in / Sign up

Export Citation Format

Share Document